Results of the I-SPY 2 TRIAL found that the neoadjuvant combination of T-DM1 plus pertuzumab resulted in a greater benefit to HER2-positive breast cancer patients compared with paclitaxel plus trastuzumab.
Prostate cancer patients who kept up a moderate to high level of physical activity had better survival prognoses compared with their more sedentary counterparts.
Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.
A new study found that half of women age 40 to 44 evaluated at an academic practice qualified for annual mammography screening for breast cancer.
More than half of women undertreated for their ductal carcinoma in situ may develop a recurrence of the disease or invasive breast cancer within 10 years, according to a study presented at the 2016 American Society of Breast Surgeons Annual Meeting.
A new analysis of the TEXT and SOFT trials examines the absolute effect of exemestane plus ovarian suppression vs tamoxifen across patients with different recurrence risks.
Men who receive pharmacologic androgen deprivation therapy as part of their treatment for prostate cancer may be at higher risk for depression.
While continuing to warn against use of laparoscopic power morcellators for the removal of uterus or uterine fibroids in most women, the FDA is allowing the marketing of a containment system for use with certain power morcellators to isolate tissue not suspected to be cancerous.
Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.
Using simulation modeling, researchers found that PSA screening can be cost-effective if men with low-risk prostate cancer do not undergo treatment and if clinicians use restrictive criteria to make a decision to biopsy.